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BRCA1 and BRCA2 germline mutations contribute to a significant number of familial and hereditary breast
and/or ovarian cancers. The proportion of high-risk families with breast and/or ovarian cancer cases due to
mutations in these tumor suppressor genes varies widely among populations.
In some population, a wide spectrum of different mutations in both genes are present, whereas in other groups
specific mutations in BRCA1 and BRCA2 have been reported with high frequency. Most of these mutations are
prevalent in restricted populations as consequence of a founder effect.
The comparison of haplotypes between families with the same mutation can distinguish whether high-frequency
alleles derive from an older or more recent single mutational event or whether they have arisen independently
more than once.
Here, we review some of the most well-known and significant examples of founder mutations in BRCA genes
found in European and non-European populations.
In conclusion, the identification of the ethnic group of families undergoing genetic counseling enables the
geneticist and oncologist to make more specific choices, leading to simplify the clinical approach to genetic
testing carried out on members of high-risk families. Futhermore, the high frequency of founder mutations,
allowing to analyze a large number of cases, might provide accurate information regarding their penetrance.
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introduction
About 5%–10% of breast cancer (BC) and ovarian cancer (OC)
are hereditary and 30%–50% of these are due to mutations,
inherited in a dominant autosomic manner, in the susceptibility
genes, BRCA1 (MIN 113705) and BRCA2 (MIN 600185),
localized respectively on chromosomes 17q21 and 13q12 [1].
In both cases the variants are distributed uniformly along the
entire coding region and intronic sequences flanking each exon;
in order to identify such mutations it is therefore necessary to
examine the whole sequence of both the genes.
Since most of the mutations involved are at high penetrance,
women carriers have an 80%–90% lifetime risk of developing
these neoplasias [2, 3].
Women who carry BRCA1 mutations are particularly
susceptible to the development of a BC before age 35–40
and also of an OC with a probability rate of, respectively,
45%–60% and 20%–40%, whereas women who inherit
a BRCA2 mutation present a 25%–40% risk of developing
a BC and a 10%–20% risk of an OC [4–6].
The presence of a mutation in the gene BRCA2 in men
leads to a risk of BC of 5%–10% and an increased risk
of developing prostatic or pancreatic tumors, while there
is a much lower risk in male carriers of BRCA1 mutations
[7, 8].
The incidence of mutations in high-risk families varies widely
among different populations; some present a wide spectrum of
different mutations, while in particular ethnic groups specific
mutations show a high frequency due to a founder effect.
Founders are small groups of people who have remained
isolated with consequent interbreeding and the result that
a normally rare mutation continues to be present and
becomes more common within the population.
The comparison of haplotypes between families with the
same mutation can distinguish whether high-frequency alleles
derive from an older or more recent single mutational event or
whether they have arisen independently more than once [9].
The aim of this review is to examine several populations
where founder mutations have been identified in the BRCA1
and BRCA2 genes (Tables 1 and 2). The identification of the
ethnic group of families undergoing genetic counseling
enables the geneticist and oncologist to make more specific
choices, leading to simplify the clinical approach to genetic
testing carried out on members of high-risk families.
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founder effect among the Ashkenazi
Jews
The well-known example of a founder effect is that of the
Ashkenazi Jews population. Ashkenazi is the term used to
describe Jews who have ancestors from Eastern and Central
Europe, such as Germany, Poland, Lithuania, Ukraine and
Russia. Today, most of the world’s 10 million Ashkenazi Jews
live in the United States, Israel, South America, South Africa,
Australia and New Zealand.
Although only 10% of cases of BC/OC is due to genetic
predisposition, the hereditary proportion of such tumors is
much higher in Ashkenazi Jews since they often carry one of
three founder mutations [5–10]. The BRCA1-185delAG
mutation is found in 1% of these and contribute to 16%–20%
of BC diagnosed before age 50 [3–11]. A second founder
mutation in the BRCA1 gene, 5382insC, is found in 0.13% of
this population [11].
The third founder mutation, 6174delT in the BRCA2 gene,
has a frequency of 1.52% in Ashkenazi [11]. Eight percent of
Ashkenazi women with BC diagnosed before age 42 and 7%
of those with BC at age 42–50, with a strong family history of
BC or OC, are carriers of this mutation [12].
The overall rate of these three founder mutations is 2.6%
(1/40) compared with the rate of 0.2% (1/500) of mutation
carriers in BRCA1/2 in the general population [11, 12].
A combined analysis of several studies based on 22 different
Ashkenazi populations has shown that BC lifetime risk is
similar in carriers of the 185delAG and 5382insC mutations
(respectively of 64% and 67%), whereas it is much lower for the
6174delT mutation (43%). This difference is particularly
marked at age 50 (8% versus 36% when the first two
mutations are combined) [13]. The corresponding OC lifetime
risk is respectively of 14%, 33% and 20% in carriers of the
185delAG, 5382insC and 6174delT mutations, respectively
[13, 14].
With regard to other neoplasias, although several studies
have reported that founder mutations in BRCA1 lead to
a higher risk of developing colorectal cancer and that there
exists an association between the presence of the founder
mutation 6174delT and the risk of developing a lymphoma and
prostate cancer [15, 16], there is still considerable discordance
between the different published data (Table 1) [17, 18].
The 5382insC mutation has been identified in several
countries, as Russia, Poland, Czech Republic and Lithuania,
where it accounts, respectively, 94%, 60%, 33% and 50% of the
BRCA1/2 gene mutations [19–24]. In subjects with a family
history of BC/OC, the frequency in Russia is of 11%, in
Hungary of 14% [25], in Greece of 8% [26], in Germany of 4%,
in France [27], in Italy of 3% [28] and in Canada of 13% [29].
On the contrary, a low frequency has been found in the
Scandinavian countries, in Belgium and in Holland. It is
thought that this mutation probably originated in the Baltic
area 38 generations ago, with a gradual decrease going from
east to west. A haplotype analysis indicates the likelihood of
a single founder both in Europe and in North America for
5382insC mutations [30].
Table 1. BRCA1/2 founder mutations in European populations
Population Mutation Reference
BRCA1 BRCA2
Ashkenazi Jews 185delAG [3, 11]
5832insC [11, 19–26, 30]
Icelanders 6174delT [11, 12]
995delG [31]
Norwegians 1675delA [35, 36]
816delGT [35, 36]
3347delAG [35, 36]
1135insA [35–37]
Finns IVS11 + 3A>G [38]
9345 + 1G>A [38]
C7708T [38]
T8555G [38]
Swedes 3171ins5 [39–41]
French 3600del11 [42]
Dutch 2804delAA [49]
IVS12-1643del3835 [48]
5579insA [48]
6503delTT [48]
Italians (Calabria) 5083del19 [64, 65]
Italians (Sardinia) 8765delAG [68, 69]
The table describes the most significant examples of founder mutations in
European populations reported in the text.
Table 2. BRCA1/2 founder mutations in non-European populations
Population Mutation Reference
BRCA1 BRCA2
French-Canadians
(Quebec)
C4446T [43–45]
8765delAG [43–45]
3398delAAAAG [43–45]
R1443X [46]
Hispanics (South
California)
S995X [52]
2552delC [52]
Hispanics (Columbia) 3450delCAAG [53]
A1708E [53]
3034delACAA [53]
Afro-Americans 943ins10 [54]
1832del5 [54]
5296del4 [54]
IVS13 + 1G>A [55]
South Africans E881X [56]
Iraqi/Iranian Jews Tyr978X [57]
Chineses 1081delG [58]
Japaneses Q934X [59, 60]
L63X [59, 60]
5802delAATT [59, 60]
Malaysians 2846insA [61]
Filipinos 4265delCT [62]
4859delA [62]
5454delC [62]
Pakistanis S1503X [63]
R1835X [63]
The table describes the most significant examples of founder mutations in
non-European populations reported in the text.
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founder mutations in Europe
Founder mutations are found in several European populations.
In Iceland, the most common founder mutation is 999del5 in
the BRCA2 gene [31]. It occurs in 0.4% of this population and
is found in 8.5% and 7.9%, respectively, of BC and OC patients,
but does not appear to contribute to the development of other
tumor types [32]. Another founder mutation identified in this
population is G5193A in BRCA1 gene, although this is
extremely rare and is present in only 1% of cases of BC/OC
[33, 34].
In Norway, hereditary forms of BC and OC involve four
main founder mutations, 1675delA, 816delGT, 3347delAG
and 1135insA. The first three originate from the southwestern
region of the country, while the fourth is from the south-east.
Overall, they represent 68% of BRCA1 mutations [35]. All
four mutations are at high penetrance with regard to both
diseases in Norwegian population [36].
The 1135insA mutation has also been reported in other
ethnic groups; nevertheless, allelotyping of Norwegian,
French-Canadian, Italian and German families has led to
different results, which would indicate an independent origin
of this mutation in each of the examined populations [37].
In Finland, 11 recurrent mutations with a founder effect
have been identified and these represent 84% of all the
mutations found in the BRCA1/2 genes. Some of these are
exclusive to the Finnish population, such as IVS11 + 3A>G
in BRCA1 and 9345 + 1G>A, C7708T, T8555G in BRCA2
genes. Others have been found in other countries, although
in some of these haplotype analysis has shown an independent
origin (C4446T-BRCA1, 3604delTT-BRCA2) [38].
The most common mutation found in Sweden is BRCA1-
3171ins5; in the western region of the country it accounts for
70% of the mutations in the BRCA1/2 genes. Mutation carriers
have a conserved haplotype of 3.7 cM which is thought to have
originated about 50 generations ago [39, 40]. Penetrance for
BC/OC at age 70 is estimated between 59% and 93% [41].
In 2004, a study carried out in France involving high-risk
families showed the presence of two particularly frequent
mutations in BRCA1: 3600del11 and G1710X, which represent
37% and 15%, respectively, of all the mutations identified.
The haplotype analysis of the families carrying the
mutation 3600del11, all originating from Alsace–Lorraine,
revealed the presence of a common allele, indicating
a founder effect. Although this mutation is found in many
different geographical areas, it is more common in France.
The mutation G1710X would appear to be specific to the
French but the analysis of its haplotype has less conclusive
and needs further confirmation [42].
The large number of founder mutations identified in the
population of Quebec originate from France since the 6.5
million French-Canadian are descendents of the groups who
colonized La Nouvelle France between 1608 and 1795. Among
these, the most common founder mutations are BRCA1-
C4446T, BRCA2-8765delAG and BRCA2-3398delAAAAG,
which is found in 1.7% of women affected by BC diagnosed
before age 41 and in 1.3% of women with OC [43–45].
In 2005, Vezina et al. [46] described for the first time not
only the molecular but also the genealogical features of the
nonsense mutation BRCA1-R1443X, recurrent in French-
Canadians. A highly conserved haplotype was identified in
18 families, indicating that this is a founder mutation within
the Quebec population. Furthermore, reconstruction of the
genealogy of these families has made it possible to identify
the founder couple with the highest probability of having
introduced the mutation into the population and also to
detect the presence of a geographical concentration in its
diffusion pattern (Table 2).
In 2001, the German Consortium for Hereditary Breast and
Ovarian Cancer identified a large number of recurrent
mutations with a common haplotype [47].
A deletion of exon 17 was found in 3% of high-risk
families and in 6% of families without mutations. This
accounted for 8% of all the BRCA1 mutations, indicating that
it might be a founder mutation within the German
population [48].
Several founder mutations in BRCA1/2 have been
identified in Holland [49]. These include BRCA1-2804delAA,
also found in Belgium, which accounts for 24% of all BRCA1/2
mutations and which probably originated 200 years ago
(32 generations); its frequency has increased as a result of
the isolation of these two countries immediately after the
second World War [50].
The mutations IVS12-1643del3835 in BRCA1 and 5579insA
in BRCA2 are found in families from two different geographical
areas, limited to the southwest region of Holland, which
became repopulated as a result of religious conflicts. It is no
coincidence that these two mutations are mainly found
respectively in Catholic and Protestant families [49].
Another Dutch founder mutation is 6503delTT, which,
together with 5579insA in BRCA2 accounts for 62% of
hereditary BC and OC linked to this gene (Table 1) [49].
The founder mutation A339G (R71G) originates from Spain
and is also found in French and British families of Spanish
origin [51]. Several other founder mutations have been
identified in Lithuania and in Poland (4153delA and C61G in
BRCA1) [21–24].
founder mutations in other countries
In America, Hispanic people constitutes 14% of the total
population. A study conducted in South California on high-risk
families showed several recurrent mutations indicated as
founder mutations by allelotyping. Some of these, such as
S995X and 2552delC in BRCA1, are present only in families of
Latin-American, Caribbean or Spanish origin [52]. These
results, however, cannot be applied to the Hispanic population
of Colombia, which presents three different founder mutations
(3450delCAAG and A1708E in BRCA1 and 3034delACAA in
BRCA2), indicating that different strategies of risk evaluation
are needed for Hispanic populations of South America and for
those of the United States [53].
Among Afro-Americans, the mutational spectrum ofBRCA1/2
is not been well characterized than that of Caucasian peoples,
but is nevertheless unique. Several recurrent mutations have
been found and in three of these (943ins10, 1832del5 and
5296del4 in BRCA1), haplotype analysis has shown a
common origin [54]. The first of these, in fact, is extremely
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old and comes from West Africa. Recently, a fourth recurrent
mutation, IVS13 + 1G>A, has been found in BRCA1 and
identified as a potential Afro-American founder [55].
The mutation E881X in BRCA1 gene is a founder mutation
in South African families. Genealogical studies have identified
three possible founder couples, who arrived in the area from
France in 1600 [56].
BRCA1-Tyr978X is a founder mutation detected in 1% of
non-Ashkenazi Jews of Iraqi or Iranian origin. The limited
ethnic occurrence of the Tyr978X-BRCA1 mutation in Jews
indicates that it originated from a common Jewish ancestor,
which is not so in the case of the French-Canadian families in
which it has been found [57].
With regard to the Far East, several recurrent mutations have
been identified in the Chinese population and one of these,
1081delG in BRCA1, has a founder effect. It is interesting to
note that carriers of these mutations all come from South
China (Hong Kong), indicating that there may well be
a different genetic background between the north and the
south of the country [58].
In Japan, the cumulative frequency of BRCA1 and BRCA2
mutations is of 32%, similar to that of Caucasian populations.
Two founder mutations have been identified in BRCA1, Q934X
and L63X, the latter exclusively in the eastern region of the
country and one in BRCA2, 5802delAATT [59, 60]. Founder
mutations have been also identified in Malaysia (BRCA1-
2846insA), Philippines (BRCA2-4265delCT and 4859delA,
BRCA1-5454delC) and Pakistan (BRCA1-S1503X and
R1835X); of all the Asian countries, the latter has the highest
rate of BC/OC [61–63] (Table 2).
founder mutations in Italy
In 2004, the Italian Consortium of Hereditary Breast and
Ovarian Cancer (nine Units) has established that the
prevalence of BRCA1/2 mutations in Italy is 23%, following an
analysis of 1758 families, 405 of which carriers of pathological
mutations, 251 in BRCA1 and 154 in BRCA2. The genetic
screening of this group of families showed different expressivity
according to the type of tumor considered and allelic
heterogeneity in both genes. Only a few of these mutations
resulted to be recurrent in particular geographical areas [64].
In 2001, Baudi et al. [65] described for the first time an
example of founder mutation in the Italian population. The
screening of the whole BRCA1 gene was carried out on 24
patients with BC and/or OC who belonged to unrelated
families and showed a high rate of the 5083del19 mutation
(four of 24 cases). All the families with this mutation originated
from Calabria and haplotype analysis carried out on the
probands and on the healthy family members showed
a common allele. This indicated a possible founder effect, in
concordance with the genetic background of the Calabrian
population, which is homogeneous and associated with
negligible immigratory phenomena. A North American
study carried out on 116 women of Italian origin with
primary BC or OC showed this mutation in five of the
families involved, three of which of Calabrian origin [66].
These data confirm that this is a founder mutation of the
Italian population, most probably originating in Calabria,
although the presence of four families carrying the mutation
identified in the genetic screening of 106 patients of Sicilian
origin indicates that it might well be of Southern Italian
origin. Only a haplotype analysis will make it possible to
understand if all these families originating from two close
regions of the south of Italy (Calabria and Sicily) have
a common ancestor [67].
Another regional founder effect has been demonstrated in
Italy for the mutation BRCA2-8765delAG. In 2002, Palmieri
et al. found this mutation in four Sardinian families with the
same haplotype, at the rate of 1.7% in a group of patients with
BC. This founder mutation was identical to that observed in
French-Canadian families [69], but involved a different
haplotype (Table 1) [68].
In Tuscany, the analysis of 11 families carrying the mutation
1499insA in BRCA1 showed a specific haplotype associated with
the mutation, also found fairly frequently in the rest of the
population. It has therefore been indicated that this is probably
due to a founder effect [70].
Several other recurrent mutations have been identified in
other limited areas of Italy, but only genetic screening carried
out on a larger number of cases within the various regions of
the country will make it possible to reach more definite
conclusions regarding the presence of a founder effect.
conclusions
Identification of founder mutations in the various ethnic
groups is an extremely important step towards the
improvement of genetic counseling since it makes possible to
use a more specific approach to molecular testing that would
also be cheaper and quicker. A less expensive mutation
detection strategy might also allow to extend genetic counseling
and testing to families with a low hereditary history.
The high frequency of founder mutations, allowing to
analyze a large number of cases, might provide accurate
information regarding their penetrance. Furthermore, the
evidence of differences in susceptibility and in age onset of
cancer among carrier of a specific mutation could make it
possible to define the role and importance of risk-modifying
factors with the resulting improved disease management.
references
1. Szabo CI, King MC. Inherited breast and ovarian cancer. Hum Mol Genet 1995;
4: 1811–1817.
2. Neuhausen S, Gilewski T, Norton L et al. Recurrent BRCA2 6174delT
mutations in Ashkenazi Jewish women affected by breast cancer. Nat Genet
1996; 13: 126–128.
3. Struewing JP, Abeliovich D, Peretz T et al. The carrier frequency of the
BRCA1 185delAG mutation is approximately 1 percent in Ashkenazi Jewish
individuals. Nat Genet 1995; 11: 198–200.
4. Brose MS et al. Cancer risk estimates for BRCA1 mutation carriers identifı`ed
in a risk evaluation program. J Nat Cancer Inst 2002; 9418: 1365–1372.
5. Robles-Diaz L, Goldfrank DJ, Kauff ND et al. Hereditary ovarian cancer in
Ashkenazi Jews. Fam Cancer 2004; 3: 259–264.
6. Antoniou A, Pharoah PD, Narod S et al. Average risks of breast and ovarian
cancer associated with BRCA1 or BRCA2 mutations detected in case series
unselected for family history: a combined analysis of 22 studies. Am J Hum
Genet 2003; 72: 1117–1130.
symposium article Annals of Oncology
vi96 | Ferla et al. Volume 18 | Supplement 6 | June 2007
7. Liede A, Karlan BY, Narod SA. Cancer risks for male carriers of germline
mutations in BRCA1 or BRCA2: a review of the literature. J Clin Oncol 2004;
22: 735–742.
8. Giordano SH. A review of the diagnosis and management of male breast cancer.
Oncologist 2005; 10: 471–479.
9. Friedman LS, Szabo CI, Ostermeyer EA et al. Novel inherited mutations and
variable expressivity of BRCA1 alleles, including the founder mutation 185delAG
in Ashkenazi Jewish families. Am J Hum Genet 1995; 57: 1284–1297.
10. Rubinstein WS. Hereditary breast cancer in Jews. Fam Cancer 2004; 3:
249–257.
11. Roa BB, Boyd AA, Volcik K et al. Ashkenazi Jewish population frequencies for
common mutations in BRCA1 and BRCA2. Nat Genet 1996; 14: 185–187.
12. Neuhausen S, Gilewski T, Norton L et al. Recurrent BRCA2 6174delT
mutations in Ashkenazi Jewish women affected by breast cancer. Nat Genet
1996; 13: 126–128.
13. Antoniou AC, Pharoah PD, Narod S et al. Breast and ovarian cancer risks to
carriers of the BRCA1 5382insC and 185delAG and BRCA2 6174delT
mutations: a combined analysis of 22 population based studies. J Med Genet
2005; 42: 602–603.
14. Satagopan JM, Boyd J, Kauff ND et al. Ovarian cancer risk in Ashkenazi
Jewish carriers of BRCA1 and BRCA2 mutations. Clin Cancer Res 2002; 8:
3776–3781.
15. Kadouri L, Hubert A, Rotenberg Y et al. Cancer risks in carriers of the BRCA1/2
Ashkenazi founder mutations. J Med Genet 2007.
16. Kirchhoff T, Kauff ND, Mitra N et al. BRCA mutations and risk of prostate
cancer in Ashkenazi Jews. Clin Cancer Res 2004; 10: 2918–2921.
17. Kirchhoff T, Satagopan JM, Kauff ND et al. Frequency of BRCA1 and BRCA2
mutations in unselected Ashkenazi Jewish patients with colorectal cancer.
J Natl Cancer Inst 2004; 96: 68–70.
18. Hamel N, Kotar K, Foulkes WD. Founder mutations in BRCA1/2 are not
frequent in Canadian Ashkenazi Jewish men with prostate cancer. BMC Med
Genet 2003; 4: 7.
19. Sokolenko AP, Mitiushkina NV, Buslov KG et al. High frequency of BRCA1
5382insC mutation in Russian breast cancer patients. Eur J Cancer 2006; 42:
1380–1384.
20. Gorski B, Byrski T, Huzarski T et al. Founder mutations in the BRCA1 gene in
Polish families with breast-ovarian cancer. Am J Hum Genet 2000; 66:
1963–1968.
21. Grzybowska E, Sieminska M, Zientek H et al. Germline mutations in the BRCA1
gene predisposing to breast and ovarian cancers in Upper Silesia population.
Acta Biochim Pol 2002; 49: 351–356.
22. Pohlreich P, Zikan M, Stribrna J et al. High proportion of recurrent germline
mutations in the BRCA1 gene in breast and ovarian cancer patients from the
Prague area. Breast Cancer Res 2005; 7: 728–736.
23. Ciernikova S, Tomka M, Kovac M et al. Ashkenazi founder BRCA1/BRCA2
mutations in Slovak hereditary breast and/or ovarian cancer families. Neoplasma
2006; 53: 97–102.
24. Gronwald J, Elsakov P, Gorski B et al. High incidence of 4153delA BRCA1 gene
mutations in Lithuanian breast and breast-ovarian cancer families. Breast Cancer
Res Treat 2005; 94: 111–113.
25. Ramus SJ, Kote-Jarai Z, Friedman LS et al. Analysis of BRCA1 and BRCA2
mutations in Hungarian families with breast or breast–ovarian cancer. Am J Hum
Genet 1997; 60: 1242–1246.
26. Ladopoulou A, Kroupis C, Konstantopoulou I et al. Germ line BRCA1 & BRCA2
mutations in Greek breast/ovarian cancer families: 5382insC is the most
frequent mutation observed. Cancer Lett 2002; 185: 61–70.
27. Stoppa-Lyonnet D, Laurent-Puig P, Essioux L et al. BRCA1 sequence variations
in 160 individuals referred to a breast/ovarian family cancer clinic. Am J Hum
Genet 1997; 60: 1021–1030.
28. Caligo MA, Ghimenti C, Cipollini G et al. BRCA1 germline mutational spectrum in
Italian families from Tuscany: a high frequency from novel mutations. Oncogene
1996; 13: 1483–1488.
29. Simard J, Tonin P, Durocher F et al. Common origins of BRCA1 mutations
in Canadian breast and ovarian cancer families. Nat Genet 1994; 8:
392–398.
30. Backe JMD, Hofferbert SMD, Skawran B et al. Frequency of BRCA1
mutation 5382insC in German breast cancer patients. Gynecol Oncol 1999;
2: 402–406.
31. Thorlacius S, Olafsdottir G, Tryggvadottir L et al. A single BRCA2 mutation in
male and female breast cancer families from Iceland with varied cancer
phenotypes. Nat Genet 1996; 13: 117–119.
32. Johannesdottir G, Gudmundsson J, Bergthorsson JT et al. High prevalence of the
999del5 mutation in Icelandic breast and ovarian cancer patients. Cancer Res
1996; 56: 3663–3665.
33. Bergthorsson JT, Jonasdottir A, Johannesdottir G et al. Identification of a novel
splice-site mutation of the BRCA1 gene in two breast cancer families: screening
reveals low frequency in Icelandic breast cancer patients. Hum Mutat 1998;
(Suppl 1): 195–197.
34. Rafnar T, Benediktsdottir KR, Eldon BJ et al. BRCA2, but not BRCA1, mutations
account for familial ovarian cancer in Iceland: a population-based study. Eur J
Cancer 2004; 40: 2788–2793.
35. Moller P, Heimdal K, Apold J et al. Genetic epidemiology of BRCA1 mutations in
Norway. Eur J Cancer 2001; 37: 2428–2434.
36. Heimdal K, Maehle L, Apold J et al. The Norwegian founder mutations in BRCA1:
high penetrance confirmed in an incident cancer series and differences observed
in the risk of ovarian cancer. Eur J Cancer 2003; 39: 2205–2213.
37. Rudkin TM, Hamel N, Galvez M et al. The frequent BRCA1 mutation 1135insA
has multiple origins: a haplotype study in different populations. BMC Med Genet
2006; 7: 15.
38. Sarantaus L, Huusko P, Eerola H et al. Multiple founder effects and geographical
clustering of BRCA1 and BRCA2 families in Finland. Eur J Hum Genet 2000; 8:
757–763.
39. Bergman A, Einbeigi Z, Olofsson U et al. The western Swedish BRCA1 founder
mutation 3171ins5; a 3.7 cM conserved haplotype of today is a reminiscence of
a 1500-year-old mutation. Eur J Hum Genet 2001; 9: 787–793.
40. Bergman A, Flodin A, Engwall Y et al. A high frequency of germline BRCA1/2
mutations in western Sweden detected with complementary screening
techniques. Fam Cancer 2005; 4: 89–96.
41. Einbeigi Z, Bergman A, Kindblom LG et al. A founder mutation of the BRCA1
gene in western Sweden associated with a high incidence of breast and ovarian
cancer. Eur J Cancer 2001; 37: 1904–1909.
42. Muller D, Bonaiti-Pellie´ C, Abecassis J et al. BRCA1 testing in breast and/or
ovarian cancer families from northeastern France identifies two common
mutations with a founder effect. Fam Cancer 2004; 3: 15–20.
43. Tonin PN, Mes-Masson A-M, Narod SA et al. Founder BRCA 1 and BRCA 2
mutations in French Canadian ovarian cancer cases unselected for family history.
Clin Genet 1999; 55: 318–324.
44. Tonin PN, Perret C, Lambert JA et al. Founder BRCA1 and BRCA2 mutations in
early-onset French Canadian breast cancer cases unselected for family history.
Int J Cancer 2001; 95: 189–193.
45. Oros KK, Leblanc G, Arcand SL et al. Haplotype analysis suggest common
founders in carriers of the recurrent BRCA2 mutation, 3398delAAAAG, in
French Canadian hereditary breast and/ovarian cancer families. BMC Med
Genet 2006; 7.
46. Vezina H, Durocher F, Dumont M et al. Molecular and genealogical
characterization of the R1443X BRCA1 mutation in high-risk French-Canadian
breast/ovarian cancer families. Hum Genet 2005; 117: 119–132.
47. German Consortium for Hereditary Breast and Ovarian Cancer. Comprehensive
analysis of 989 patients with breast or ovarian cancer provides brca1 and brca2
mutation profiles and frequencies for the german population. Int J Cancer 2002;
97: 472–480.
48. Hartmann C, John AL, Klaes R et al. Large BRCA1 gene deletions are found
in 3% of German high-risk breast cancer families. Hum Mutat 2004; 24:
534.
49. Zeegers MPA, van Poppel F, Vlietinck R et al. Founder mutations among the
Dutch. Eur J Hum Genet 2004; 12: 591–600.
50. Peelen T, van der Vliet M, Petrij-Bosch A et al. A high proportion of novel
mutations in BRCA1 with strong founder effects among Dutch and Belgian
hereditary breast and ovarian cancer families. Am J Hum Genet 1997; 60:
1041–1049.
Annals of Oncology symposium article
Volume 18 | Supplement 6 | June 2007 doi:10.1093/annonc/mdm234 | vi97
51. Vega A, Campos B, Bressac-de-Paillerets B et al. The R71G BRCA1 is a founder
spanish mutation and leads to aberrant splicing of the transcript. Hum Mutat
2001; 419: 1–6.
52. Weitzel JN, Lagos V, Blazer KR et al. Prevalence of BRCA mutations and founder
effect in high-risk Hispanic families. Cancer Epidemiol Biomarkers Prev 2005;
14: 1666–1671.
53. Torres D, Usman Rashid M, Gil F et al. High proportion of BRCA1/2 founder
mutations in Hispanic breast/ovarian cancer families from Colombia. Breast
Cancer Res Treat .
54. Olopade OI, Fackenthal JD, Dunston G et al. Breast cancer genetics in African
Americans. Cancer 2003; 97 (Suppl): 236–245.
55. Pal T, Permuth-Wey J, Holtje T et al. BRCA1 and BRCA2 mutations in a study of
African American breast cancer patients. Cancer Epidemiol Biomarkers Prev
2004; 13: 1794–1799.
56. Reeves MD, Yawitch TM, van Der Merwe NC et al. BRCA1 mutations in South
African breast and/or ovarian cancer families: evidence of a novel founder
mutation in Afrikaner families. Int J Cancer 2004; 110: 677–682.
57. Quintana-Murci L, Gal I, Bakhan T et al. The Tyr978X BRCA1 mutation:
occurrence in non-Jewish Iranians and haplotype in French-Canadian and non-
Ashkenazi Jews. Fam Cancer 2005; 4: 85–88.
58. Khoo US, Chan KY, Cheung AN et al. Recurrent BRCA1 and BRCA2 germline
mutations in ovarian cancer: a founder mutation of BRCA1 identified in the
Chinese population. Hum Mutat 2002; 486.
59. Ikeda N, Miyoshi Y, Yoneda K et al. Frequency of BRCA1 and BRCA2 germline
mutations in japanese breast cancer families. Int J Cancer 2001; 91: 83–88.
60. Sekine M, Nagata H, Tsuji S et al. Mutational analysis of BRCA1 and BRCA2 and
clinicopathologic analysis of ovarian cancer in 82 ovarian cancer families: two
common founder mutations of BRCA1 in Japanese population. Clin Cancer Res
2001; 7: 3144–3150.
61. Lee ASG, Ho GH, Oh PC et al. Founder mutation in the BRCA1 gene in Malay
breast cancer patients from Singapore. Hum Mutati 2003; 633.
62. De Leon Matsuda ML, Liede A, Kwan E et al. BRCA1 and BRCA2 mutations among
breast cancer patients from the Philippines. Int J Cancer 2002; 98: 596–603.
63. Rashid MU, Zaidi A, Torres D et al. Prevalence of BRCA1 and BRCA2 mutations
in Pakistani breast and ovarian cancer patients. Int J Cancer 2006; 119:
2832–2839.
64. Cipollini G, Tommasi S, Paradiso A et al. Genetic alterations in hereditary breast
cancer. Ann Oncol 2004; 15 (Suppl 1): I7–I13.
65. Baudi F, Quaresima B, Grandinetti C et al. Evidence of a founder mutation of
BRCA1 in a highly homogeneous population from southern Italy with breast/
ovarian cancer. Hum Mutat 2001; 18: 163–164.
66. Nedelcu R, Liede A, Aube J et al. BRCA mutations in Italian breast/ovarian
cancer families. Eur J Hum Genet 2002; 10: 150–152.
67. Russo A, Calo V, Agnese V et al. BRCA1 genetic testing in 106 breast and
ovarian cancer families from southern Italy (Sicily): a mutation analyses. Breast
Cancer Res Treat 2007.
68. Pisano M, Cossu A, Persico I et al. Identification of a founder BRCA2 mutation in
Sardinia. Br J Cancer 2000; 82: 553–559.
69. Tonin PN, Mes-Masson AM, Futreal PA et al. Founder BRCA1 and BRCA2
mutations in French Canadian breast and ovarian cancer families. Am J Hum
Genet 1998; 63: 1341–1351.
70. Caligo MA, Ghimenti C, Cipollini G et al. BRCA1 germline mutational spectrum in
Italian families from Tuscany: a high frequency of novel mutations. Oncogene
1996; 13: 1483–1488.
symposium article Annals of Oncology
vi98 | Ferla et al. Volume 18 | Supplement 6 | June 2007
